Core Viewpoint - The company reported a decline in revenue for 2025, while net profit showed growth, indicating a mixed performance in the financial results [1] Financial Performance - The company achieved an operating revenue of 82.532 billion yuan, a year-on-year decrease of 9.33% [1] - The net profit attributable to shareholders was 8.113 billion yuan, reflecting a year-on-year increase of 5.42% [1] - Basic earnings per share were reported at 1.54 yuan [1] Dividend Distribution - The company proposed a cash dividend of 6.1 yuan per 10 shares (including tax) [1] Sales and Profitability - The sales volume of self-produced cement clinker was 26.5 million tons, showing a year-on-year decline of 1.13%, which is better than the average decline in the cement industry [1] - The comprehensive gross profit margin for self-produced products was 27.76%, an increase of 2.95 percentage points compared to the same period last year [1]

Core Viewpoint - The company, founded in 1929 and listed in December 2011, has faced revenue declines but is focusing on brand transformation and high-end market positioning to enhance profitability and attract younger consumers [1][4]. Group 1: Financial Performance - For FY2025, the company reported a revenue of HKD 89.656 billion, a year-on-year decline of 17.5%, and a net profit attributable to shareholders of HKD 5.916 billion, down 9.0% [1]. - The revenue and net profit compound annual growth rates (CAGR) from FY2012 to FY2017 were -2.0% and -4.5%, respectively, while from FY2018 to FY2024, they improved to +10.6% and +8.0% [2]. Group 2: Market Trends - The overall consumption of gold jewelry is weakening due to rising gold prices, but niche markets like ancient gold and national trend concepts are experiencing growth [3]. - The market size for gold products in China is projected to reach HKD 568.8 billion in 2024, with ancient gold's market share increasing from 4% in 2018 to an expected 52% by 2028 [3]. Group 3: Store Operations - The company is transitioning from store expansion to contraction, with a net decrease of 833 stores in FY2025 and an additional 611 stores in FY2026H1 [4]. - The company is focusing on high-end city layouts and opening new high-end image stores to enhance brand appeal, with high-end stores outperforming average sales in their respective areas [4]. Group 4: Product Strategy - The company categorizes its gold jewelry products into pricing and valuation segments, with pricing products accounting for 14.6% of total revenue and showing a CAGR of 34.5% from FY2021 to FY2025 [3]. - Signature products are being developed to differentiate the brand, with a focus on mid-to-high-end positioning [3]. Group 5: Future Projections - The company maintains its profit forecast, expecting revenues of HKD 93.345 billion, HKD 98.380 billion, and HKD 103.276 billion for FY2026 to FY2028, with corresponding net profits of HKD 8.131 billion, HKD 8.980 billion, and HKD 9.547 billion [4].

格隆汇3月24日丨渣打集团(02888.HK)公告，3月23日耗资1524.8万英镑回购98.7万股。 ...

格隆汇3月24日丨达芙妮国际(00210.HK)公布2025年全年业绩，报告期内，营业收入增加13%至约人民 币3.635亿元；经营盈利增加28%至约人民币1.238亿元；公司股东应占盈利增加9%至约人民币1.166亿 元；每股基本盈利为人民币0.059元，建议派发末期股息每股0.02港元。 公告表示，凭借灵活的策略洞察与迅速应对多变市场，集团始终保持稳健发展的动能，并坚定沿着专注 高品质发展和长期价值的可持续道路稳步迈进。2025年度，集团营业收入总额按年同比增长13%，而经 营盈利则上升28%。这股持续向上的增长趋势，充分展现了集团持久而强韧的营运实力，更强化其在市 场中持续引领潮流、巩固长期领导地位的优势布局。 ...

Group 1 - The company, Baoshan International (03813.HK), announced the cancellation of a total of 10.665 million shares repurchased as of March 24, 2026 [1]

Core Viewpoint - Li Auto Inc. (02015.HK) has announced a share repurchase plan authorized by its board, allowing the company to repurchase up to $1 billion of its Class A ordinary shares and/or American Depositary Shares from March 24, 2026, to March 31, 2027 [1] Group 1 - The share repurchase plan is set to enhance shareholder value and reflects the company's confidence in its financial position [1] - The repurchase will be executed within a specified timeframe, indicating a strategic approach to capital management [1] - The total value of the repurchase program is capped at $1 billion, showcasing the company's commitment to returning capital to shareholders [1]

Core Viewpoint - China Jinmao (00817.HK) reported a revenue of 59.371 billion RMB for the year ending December 31, 2025, representing a year-on-year increase of 1% [1] - The company emphasizes technological innovation and aims to strengthen its competitive edge in the real estate sector through a focus on building technology and sustainable practices [1] Financial Performance - Revenue reached 59.371 billion RMB, up 1% year-on-year [1] - Gross profit was 9.221 billion RMB, reflecting a 7% increase year-on-year [1] - Profit attributable to owners was 1.253 billion RMB, an 18% increase year-on-year [1] - Core profit attributable to owners was 1.363 billion RMB, showing a 2% increase year-on-year [1] - Basic earnings per share were 0.0438 RMB [1] Strategic Focus - The company is concentrating on building technology and aims to cultivate "unicorn" businesses through technological innovation [1] - China Jinmao is enhancing its one-stop service model from design consultation to operational management, focusing on green, energy-efficient, smart, comfortable, and healthy housing [1] - The smart energy segment is focused on comprehensive energy services and green big data center operations, aiming to improve operational efficiency and contribute to environmental sustainability goals [1]

Core Viewpoint - Jiutai Bonda Energy (02798.HK) reported a significant decline in annual performance for the year ending December 31, 2025, with revenues expected to be approximately RMB 1.206 billion, a decrease of about 29.3% compared to RMB 1.706 billion in 2024 [1] Financial Performance - The total loss and comprehensive expenses for the year are approximately RMB 198 million, contrasting with a profit and comprehensive income of about RMB 440 million in 2024 [1] - Basic loss per share is expected to be around RMB 0.1236, compared to earnings per share of RMB 0.2751 in 2024 [1] - The company does not recommend declaring a final dividend for the year ending December 31, 2025, while no dividend was declared in 2024 [1] Product Strategy - The company continues to focus on premium coal as its main product, maintaining a strategy to stabilize the proportion of premium coal in its product mix [1] - Revenue generated from premium coal sales is expected to account for approximately 86.8% of total revenue for the year ending December 31, 2025, down from about 90.9% in 2024, indicating a slight decrease in revenue contribution from this segment [1]

格隆汇3月24日丨昆仑能源(00135.HK)宣布，独立非执行董事辛定华，即公司审核委员会主席、薪酬委 员会及提名委员会的成员，已获委任为首席独立非执行董事，自2026年3月24日起生效。 ...

Core Viewpoint - The launch of Pemafibrate (brand name: Paireda®) by Hoshino Corporation on Alibaba Health marks the first official online availability of this next-generation selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) [1][5]. Group 1: Product Overview - Pemafibrate has been approved by the National Medical Products Administration since April 2025 and is now available to patients through an authorized e-commerce platform [1]. - The drug has been on the market in Japan for nine years and is recognized for its efficacy in lowering triglycerides while ensuring liver and kidney safety [1][5]. Group 2: Clinical Significance - Hypertriglyceridemia is prevalent in China, with a reported incidence rate of 15% to 22.4%, yet treatment and control rates are low at 11.6% and 5.4%, respectively [3]. - Each 1 mmol/L increase in triglyceride levels raises the risk of microvascular events by 35% and the risk of type 2 diabetes by 81% [3]. - Pemafibrate demonstrates a 2500-fold stronger activation effect on PPARα compared to traditional fibrates, with a clinical trial showing a 51.8% reduction in triglycerides at a dosage of 0.4 mg/day [3]. Group 3: Target Population - Pemafibrate is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and those not achieving triglyceride targets while on statins [4][5]. - The drug has received recognition from various authoritative guidelines, including the 2023 Chinese Lipid Management Guidelines and the European Society of Cardiology guidelines, confirming its efficacy and safety [5].